This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Tolvaptan in autosomal dominant polycystic kidney ...
Journal

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Read time: 1 mins
Published:25th Mar 2020
Author: Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators.
Ref.:Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507.
DOI:10.2215/CJN.03530411.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest